ALKYLAMINE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | ALKYLAMINE | Market Cap | 9,418 Cr. | Current Price | 1,844 ₹ | High / Low | 2,449 ₹ |
| Stock P/E | 52.3 | Book Value | 300 ₹ | Dividend Yield | 0.54 % | ROCE | 16.6 % |
| ROE | 12.3 % | Face Value | 2.00 ₹ | DMA 50 | 1,679 ₹ | DMA 200 | 1,675 ₹ |
| Chg in FII Hold | 0.00 % | Chg in DII Hold | 0.00 % | PAT Qtr | 45.4 Cr. | PAT Prev Qtr | 42.3 Cr. |
| RSI | 59.5 | MACD | 47.7 | Volume | 85,972 | Avg Vol 1Wk | 73,689 |
| Low price | 1,212 ₹ | High price | 2,449 ₹ | PEG Ratio | -6.50 | Debt to equity | 0.00 |
| 52w Index | 51.1 % | Qtr Profit Var | -1.41 % | EPS | 35.2 ₹ | Industry PE | 28.7 |
📊 ALKYLAMINE shows moderate fundamentals for long-term investment. With ROE (12.3%) and ROCE (16.6%), the company demonstrates average capital efficiency. Debt-to-equity is 0.00, which is positive, but the P/E ratio (52.3) is significantly higher than the industry average (28.7), suggesting overvaluation. Dividend yield (0.54%) provides minimal passive income. The PEG ratio (-6.50) reflects negative growth expectations, raising concerns. Quarterly PAT grew slightly from 42.3 Cr. to 45.4 Cr., but profit variation (-1.41%) indicates weak momentum. EPS (35.2 ₹) is decent, but valuations remain stretched.
💡 Entry Price Zone: A favorable entry would be between 1,600 ₹ – 1,700 ₹, closer to DMA 50 (1,679 ₹) and DMA 200 (1,675 ₹), where valuations align better with long-term growth potential.
📈 Exit Strategy / Holding Period: If already holding, consider partial profit booking near 1,900–2,000 ₹ levels due to overvaluation. Long-term holding is not recommended unless ROE and ROCE improve significantly. Investors should monitor quarterly earnings and PEG ratio before committing to a 3–5 year horizon.
🌟 Positive
- Debt-free structure (debt-to-equity 0.00) ensures financial stability.
- EPS of 35.2 ₹ supports earnings visibility.
- Quarterly PAT improved slightly from 42.3 Cr. to 45.4 Cr.
- Stock trading at ~51.1% of 52-week index, leaving room for recovery if fundamentals improve.
⚠️ Limitation
- High [P/E ratio](ca://s?q=Explain_P/E_ratio) of 52.3 compared to industry average of 28.7.
- Weak [ROE](ca://s?q=Explain_ROE) (12.3%) and [ROCE](ca://s?q=Explain_ROCE) (16.6%) show average capital efficiency.
- [PEG ratio](ca://s?q=PEG_ratio_explained) of -6.50 reflects negative growth outlook.
- Dividend yield of 0.54% offers minimal passive income.
- Quarterly profit variation (-1.41%) shows weak earnings momentum.
📰 Company Negative News
- Valuation concerns due to high P/E and negative PEG ratio.
- Weak capital efficiency compared to industry peers.
- Muted institutional activity (FII and DII unchanged).
📢 Company Positive News
- Debt-free balance sheet enhances financial resilience.
- EPS of 35.2 ₹ supports long-term sustainability.
- Quarterly PAT showed slight improvement.
🏭 Industry
- Industry P/E at 28.7, much lower than company’s 52.3, highlighting sector-wide better valuations.
- Chemical sector growth driven by demand in pharma, agriculture, and specialty chemicals, but competition remains high.
✅ Conclusion
ALKYLAMINE is currently overvalued with weak efficiency metrics and negative PEG ratio, making it a moderate candidate for long-term investment. Entry should be considered only near 1,600–1,700 ₹ if fundamentals improve. Existing holders may exit around 1,900–2,000 ₹ to reduce risk exposure, as long-term growth prospects remain uncertain without stronger ROE and ROCE performance.